Skip to content
WeighLab
Menu
Ranked #320 · Grade C

ARSYNL Rx review

ARSYNL Rx is a veteran-founded (Arron Glysch) telehealth platform selling compounded semaglutide ($233/mo) and tirzepatide, either as a standard injectable ($233/mo) or a needle-free HypoSpray with six dose protocols (from $256.33/mo).

Visit ARSYNL Rx Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$233/mo (starting dose, compounded)
Tirzepatide
$233/mo (starting dose, compounded)
Coverage
Coverage not published
Brand-name
Compounded only

Semaglutide · modeled / year

$2,796

Tirzepatide · modeled / year

$2,796

Pricing verified August 2026

The Index scorecard

ARSYNL Rx scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month45/100
Price Transparency78/100
Nationwide Access24/100
Formulation Options66/100
Clinical Oversight78/100
Contract Flexibility55/100

Where the value is

  • Genuinely veteran-founded — the About page names founder Arron Glysch and recounts his own hair-loss experience while deployed overseas
  • Offers a needle-free tirzepatide HypoSpray with six published dose protocols (10mg-60mg total/month)
  • All three GLP-1 SKUs are stated to already include the consultation and shipping in the quoted price
  • LegitScript certification badge displayed on the site

The tradeoffs

  • No compounding pharmacy is named on any product page checked
  • No individual medical director or prescriber is named anywhere accessible — only 'U.S. board certified physicians' as a category
  • States served are not published on the site; product-detail intake links for two of the three products sit behind a bot-verification token gate
  • The $233-$256.33 'from' figures are floors for the lowest dose tier only

The bottom line

Best for: Cost-first shoppers who want a needle-free tirzepatide hypospray option alongside standard compounded injections, from a veteran-founded telehealth brand. ARSYNL Rx is a veteran-founded (Arron Glysch) telehealth platform selling compounded semaglutide ($233/mo) and tirzepatide, either as a standard injectable ($233/mo) or a needle-free HypoSpray with six dose protocols (from $256.33/mo).

Ranked #320 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to ARSYNL Rx.

The 24 programs nearest this one

Pricing, states and verification reflect ARSYNL Rx's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on ARSYNL Rx's site. Not medical advice; see our disclosure.

← Back to the value leaderboard